CT DCP drug director named in unauthorized cannabis inspection

The disclosure of internal documents reveals a troubling instance of potential retaliation by a state regulatory official against a cannabis industry representative. After criticizing testing protocols at a public hearing, the CEO of Affinity Grow faced an unauthorized, unannounced inspection ordered by the Drug Control division director just hours later. This incident highlights how regulatory bodies may abuse their power to silence criticism, creating a chilling effect on free speech within the industry. Internal records show the director admitted to misinterpreting testimony before ordering the investigation, which ultimately found no violations. The agency’s subsequent apologies and the official’s eventual resignation underscore the severity of this breach of trust. Such episodes demonstrate that without strict accountability mechanisms, individual agency actions can undermine regulatory legitimacy and damage relationships between government bodies and the communities they serve. This case is critically relevant to open data advocates because it illustrates the necessity of transparency in government operations. Freedom of Information Act requests served as the only means to expose the misconduct, proving that open data policies are essential tools for holding officials accountable. Without such mechanisms, abuses of power and retaliatory behavior could remain hidden, eroding public confidence and allowing harmful practices to persist unchecked in regulated industries.

Source: wshu.org
Published on 2025-09-17

CT DCP drug director named in unauthorized cannabis inspection

Related news